MedElevator
Войти в исследования Endoscopy international open · 2026
Self-assembling peptide hydrogel prevents esophageal stenosis after endoscopic submucosal dissection for esophageal squamous cell carcinoma: Multicenter prospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Urabe Yuji, Hiyama Yuichi, Asayama Naoki, Tamaru Yuzuru, Sanomura Yoji, Yoshida Shigeto, Nagata Shinji, Hiraga Yuko, Takamori Ayako, Orihashi Yasushi, Kuwai Toshio, Oka Shiro
Аннотация
BACKGROUND AND STUDY AIMS: Self-assembling peptide hydrogel (PuraStat) is a novel self-assembling peptide-based hemostatic agent that forms a transparent hydrogel upon contact with blood or bodily fluids. It has been reported to reduce the number of coagulations required with hemostatic forceps during gastrointestinal endoscopic procedures. In addition to its hemostatic effect, recent studies have suggested that PuraStat promotes wound healing. This study aimed to investigate the efficacy of PuraStat in preventing esophageal stenosis following endoscopic treatment of esophageal squamous cell carcinoma (ESCC).
PATIENTS AND METHODS: This was a single-arm, multicenter, prospective study. Patients with esophageal squamous cell carcinoma who underwent endoscopic submucosal dissection and had a post-resection ulcer involving three-quarters or more of the full circumference of the esophagus received PuraStat application twice: once immediately after the procedure and once at second-look endoscopy 2 to 4 days later. The primary endpoint was incidence of esophageal stenosis within 12 weeks after endoscopic submucosal dissection. Secondary endpoints included the number of endoscopic balloon dilation procedures required and incidence of adverse events (AEs) and serious AEs.
RESULTS: Twenty patients were enrolled, all of whom received PuraStat application. Incidence of esophageal stenosis within 12 weeks was 20% (4/20). All cases of stenosis resolved with fewer than six endoscopic balloon dilation procedures and no patients developed refractory esophageal stenosis. AEs were observed in four patients; however, all resolved with conservative management.
CONCLUSIONS: PuraStat application for post-endoscopic submucosal dissection ulcers in patients with ESCC may be useful for preventing esophageal stenosis.
PATIENTS AND METHODS: This was a single-arm, multicenter, prospective study. Patients with esophageal squamous cell carcinoma who underwent endoscopic submucosal dissection and had a post-resection ulcer involving three-quarters or more of the full circumference of the esophagus received PuraStat application twice: once immediately after the procedure and once at second-look endoscopy 2 to 4 days later. The primary endpoint was incidence of esophageal stenosis within 12 weeks after endoscopic submucosal dissection. Secondary endpoints included the number of endoscopic balloon dilation procedures required and incidence of adverse events (AEs) and serious AEs.
RESULTS: Twenty patients were enrolled, all of whom received PuraStat application. Incidence of esophageal stenosis within 12 weeks was 20% (4/20). All cases of stenosis resolved with fewer than six endoscopic balloon dilation procedures and no patients developed refractory esophageal stenosis. AEs were observed in four patients; however, all resolved with conservative management.
CONCLUSIONS: PuraStat application for post-endoscopic submucosal dissection ulcers in patients with ESCC may be useful for preventing esophageal stenosis.